Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
about
Prognostic significance of copy-number alterations in multiple myelomaContact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug deliveryMany multiple myelomas: making more of the molecular mayhemAdvances in the autologous and allogeneic transplantation strategies for multiple myelomaComparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trialsMolecular pathogenesis of multiple myeloma: basic and clinical updatesEvolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted TherapiesDrug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Development of Novel Immunotherapies for Multiple MyelomaMolecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple MyelomaCarfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factorsA phthalimide derivative that inhibits centrosomal clustering is effective on multiple myelomaInhibition of the MDM2 E3 Ligase induces apoptosis and autophagy in wild-type and mutant p53 models of multiple myeloma, and acts synergistically with ABT-737Advances in understanding prognosis in myeloma.Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03.Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Plasma cell leukemia.Bortezomib in patients with renal impairment.How I treat plasma cell leukemia.A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trialCombination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.Novel therapies in multiple myeloma for newly diagnosed nontransplant candidatesCarfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myelomaIn vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.Implications of heterogeneity in multiple myeloma.Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation.The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significancePromiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma.Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.Nucleolar stress with and without p53.
P2860
Q24643402-52E9C96E-B1F9-48A2-B982-750CAA70B523Q26795703-6C149E5B-44BA-41BA-956A-F4E2FDEF7C29Q26852892-477B311A-578D-4C1F-92FF-81097462AC0BQ27014801-8F51B313-2542-47C2-9404-F308E09775EEQ27024932-6D32A262-A60A-4629-A263-11E123CC442AQ27026205-51F91554-FC55-4BD6-9D92-D885849599DEQ27026478-E1EC5B55-1151-45AC-B885-FEF5C187DB7AQ27692033-ABDE1C6C-5609-476E-B648-BF7AA1285DBCQ28066890-BFF9D44D-5C0E-46FC-995A-A920505F23F3Q28074490-5FF1519E-B11B-44C9-B2E0-11D2F18A2C3AQ28084683-82634BC1-DB20-48E8-A700-E035E1810F03Q28480621-8362598C-8159-43F3-AEF3-E90A6D005D25Q28542684-BF87F769-60BE-4EB6-89E4-76FF32430364Q30244061-54930A1B-4337-43C6-871D-71D7E8911BADQ30275382-1694017D-5EF5-4C1F-AAF2-D6AD24A425D2Q30424188-EFAFF509-F428-430D-B6F9-ECD455708F58Q30571858-DBC7302E-228B-47D8-B975-23175599E47CQ31154933-06B2051B-1893-4723-A8F6-61F84488E53FQ33389111-F4A68770-ADD5-4EDE-9DD9-582A040E42E9Q33393995-F37E3497-0D34-4CAD-AC07-D861EEC3E769Q33396250-06C0812E-3797-414F-92AA-F20D7DA4F641Q33402555-DA77019B-257D-4C9E-BE8E-938177095DC8Q33431621-76EDF1EF-FE73-4387-9F11-5A6BEA28D433Q33627051-F84243E8-DFE3-4630-B337-E26EBDDFF8E1Q33639796-B43BC3A6-CE82-49A7-9B89-5683971E18A5Q33785935-AFEF6276-39AA-44DC-A6D4-5B824F9797CBQ33856318-6F32DCB6-1BC3-4517-8F12-64566CADEC7EQ33902726-40586AD1-1DAE-42AB-8022-5194F80876C4Q33914824-5552B2BC-2703-4FE0-9FAD-C1883626B27FQ33942495-B30EA6B7-BCB4-4CCD-952D-8C5A7305F47FQ33952805-B0B1770A-2387-4B79-B304-F10EC292AD53Q33952861-D984D917-4ED8-4C60-AA13-B2B92490E414Q34020965-9CCA0ED3-46B4-4DDA-AC34-9AB16DF16437Q34022979-9F9C991E-A4E8-49E0-8EDA-632EFD94CC83Q34063353-37BB673D-EB0B-4491-A438-91B0EAB7BB8BQ34104277-D4EB59AC-64A5-413F-81AC-17C732D23836Q34115051-CBCC728C-6FCA-4DB0-BC73-1A821B0CCB8FQ34134986-A6606DBA-1720-4BA0-A394-BDF76EEA007CQ34173892-95076781-09A2-4AC9-8EC6-375C6BE3188FQ34183329-40A5FC48-285C-48D3-826B-AD9FC23B7892
P2860
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Genetic abnormalities and surv ...... groupe Francophone du Myélome.
@en
Genetic abnormalities and surv ...... groupe Francophone du Myélome.
@nl
type
label
Genetic abnormalities and surv ...... groupe Francophone du Myélome.
@en
Genetic abnormalities and surv ...... groupe Francophone du Myélome.
@nl
prefLabel
Genetic abnormalities and surv ...... groupe Francophone du Myélome.
@en
Genetic abnormalities and surv ...... groupe Francophone du Myélome.
@nl
P2093
P50
P1433
P1476
Genetic abnormalities and surv ...... rgroupe Francophone du Myélome
@en
P2093
Anne-Marie Stoppa
Bernard Grosbois
Catherine Charbonnel
Catherine Thieblemont
Claire Mathiot
Cyrille Hulin
Denis Caillot
Frédéric Garban
Gaelle Guillerm
Gérald Marit
P304
P356
10.1182/BLOOD-2006-08-040410
P407
P577
2007-01-05T00:00:00Z